Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes | SpringerLink
Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems
Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model | Journal of Nuclear Medicine
International Clinical Cytometry Society
New Strategies for Targeting CD38 in Multiple Myeloma Take Root
Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen
CD38 expression and function in NK cells. (A) Role of CD38 in the... | Download Scientific Diagram
CD38 - Wikipedia
![Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics](https://pubs.acs.org/cms/10.1021/acs.molpharmaceut.1c00733/asset/images/acs.molpharmaceut.1c00733.social.jpeg_v03 "Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics")
Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics
JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
Immunophenotyping | plasma cells | human multiple myeloma bone marrow | Protocol | Italia
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action - Adams - 2019 - Cytometry Part A - Wiley Online Library
![PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/72ce80f2da87d037624955a597846d530a0c6052/3-Figure1-1.png "PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar")
PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar
Double CD38−/CD138− negative multiple myeloma - ScienceDirect
CD38 directed therapies for management of multiple myeloma | ITT
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Cureus | CD38: From Positive to Negative Expression after Daratumumab Treatment | Article
Blood and Hematology - CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
International Clinical Cytometry Society
CD38, A Target for Immunotherapeutic Approaches in Cancer
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formatio
Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar
A Guide to Plasma Cell Markers | Biocompare: The Buyer's Guide for Life Scientists
